---
title: "Evaluation of PET CT in the Management of Patients With Crohn's Disease."
nct_id: NCT00731809
overall_status: UNKNOWN
phase: PHASE4
sponsor: Rabin Medical Center
study_type: INTERVENTIONAL
primary_condition: "Crohn's Disease"
countries: Israel
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00731809.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00731809"
ct_last_update_post_date: 2008-12-23
last_seen_at: "2026-05-12T07:24:15.013Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Evaluation of PET CT in the Management of Patients With Crohn's Disease.

**NCT ID:** [NCT00731809](https://clinicaltrials.gov/study/NCT00731809)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Rabin Medical Center
- **Conditions:** Crohn's Disease
- **Start Date:** 2008-04
- **Completion Date:** 2010-10
- **CT.gov Last Update:** 2008-12-23

## Brief Summary

18F-FDG PET/CT (2-\[fluorine-18\] fluoro-2-deoxy-D-glucose, Positron emission tomography- CT) is a noninvasive technique that allows quantifying and precisely localizing 18F-FDG uptake in the entire body. 18F-FDG uptake is caused by increased local metabolic activity. Such increased uptake has been described not only in neoplastic lesions but also in inflammatory lesions. In this condition, uptake has been correlated with local stimulation of tumor necrosis factor, and with monocyte priming and activation. A physiologic variable uptake may be observed in the bowel, especially the cecum, and has limited the use of PET in inflammatory bowel diseases. The advantage of combined PET and CT devices lead to significant improvements in the interpretation of the bowel areas, and greatly reduces the number of false-positive findings in the gastrointestinal tract.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients suspicious for active disease:

  * Patients with suspected but undiagnosed Crohn's disease
  * Patients with serological markers of inflammation (elevated ESR, CRP or thrombocytosis) but clinically in remission
  * Patients with a stricture which might be fibrous in which case surgery is indicated or inflammatory for which medical management is indicated
  * Able to sign a consent form

Exclusion Criteria:

* Pregnancy
* Breastfeeding
* Infectious colitis determined at the initial checkup
* Allergy to iodine contrast
```

## Arms

- **1** (OTHER) — PET CT

## Interventions

- **FDG PET CT** (RADIATION) — FDG PET CT

## Locations (1)

- Rabin Medical Center, Petah Tikva, Israel — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.rabin medical center|petah tikva||israel` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00731809.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00731809*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*